Protection or damage: A dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection?

Current Opinion in Immunology

Volumn 12, Issue 4, 2000, Pages 403-408

  Bertoletti, Antonio ^a   Maini, Mala K ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION CONTROL; LIVER DISEASE; LIVER PROTECTION; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS REPLICATION;

EID: 0034126609     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00108-4     Document Type: Review

References (70)

1. Chisari F.V. Cytotoxic T cells and viral hepatitis. J Clin Invest. 99:1997;1472-1477.
2. Koziel M. The role of immune responses in the pathogenesis of hepatitis C virus infection. J Viral Hepat. 4:1997;31-41.
3. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 13:1995;29-60.
4. Cerny A., Chisari F.V. Pathogenesis of chronic hepatitis C: immunological features of hepatitis injury and viral persistence. Hepatology. 30:1999;595-601.
5. Altman J.D., Moss P.A.H., Goulder P.J.R., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., McMichael A.J., Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96.
6. Guidotti L.G., Chisari F.V. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol. 8:1996;478-483.
7. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 4:1996;25-36.
8. Tay C., Welsh R. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol. 71:1997;267-275.
9. Kagi D., Ledermann B., Burki H., Hengartner H., Zinkernagel R. CD8+ T-cell mediated protection against an intracellular bacterium by perforin-dependent cytotoxicity. Eur J Immunol. 24:1994;3068-3072.
10. Guidotti L.G., Borrow P., Brown A., McClary H., Koch R., Chisari F.V. Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte. J Exp Med. 189:1999;1555-1564. Here the authors demonstrate that LCMV replicating within hepatocytes is susceptible to noncytopathic antiviral control. This work suggests that noncytopathic mechanisms may be more active in parenchymal cells in order to preserve the functional integrity of vital organs such as the liver.
11. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science. 284:1999;825-829. Shows control of HBV replication in acutely infected chimpanzees before the peak of liver damage and T cell infiltration, highlighting the relevance of noncytopathic mechanisms of viral clearance during acute viral hepatitis in a primate model.
12. Kondo T., Suda T., Fukuyama H., Adachi M., Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med. 3:1997;409-413.
13. Guo J., Zhou H., Liu C., Aldrich C., Saputelli J., Whitaker T., Inmaculada Barrasa M., Mason W., Seeger C. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol. 74:2000;1495-1505. Demonstrates an increased rate of hepatocyte apoptosis and regeneration during control of woodchuck hepatitis virus. This work suggests that a degree of direct hepatocyte lysis is occurring during viral control and that infected cells are replaced by regenerated hepatocytes resistant to further infection.
14. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., Houghton M., Parham P., Walker C. Analysis of a successful immune response against hepatitis C virus. Immunity. 10:1999;439-449. The HCV-specific CTL response is monitored, from the liver of chimpanzees acutely infected with HCV. A multispecific CTL response acting in the early phase of infection correlates with HCV resolution. These CTLs persist in a biochemically and histologically normal liver more than a year after resolution of infection.
15. Nelson D.R., Marousis C.G., Davis G.L., Rice C.M., Wong J., Houghton M., Lau J.Y. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol. 158:1997;1473-1481.
16. Maini M.K., Boni C., Ogg G.S., King A.S., Reignat S., Lee C.K., Larrubia J.R., Webster G.J., McMichael A.J., Ferrari C.et al. Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology. 117:1999;1386-1396.
17. + T cells in peripheral blood and liver using peptide-MHC tetramers.
18. Maini M.K., Boni C., Lee C.K., Larrubia J.R., Reignat S., Ogg G.S., King A.S., Herberg J., Gilson R., Alisa A.et al. The role of virus-specific CD8+ cells in viral control and liver damage during persistent hepatitis B virus (HBV) infection. J Exp Med. 191:2000;1269-1280. The frequency and functional efficiency of HBV-specific CTLs directly from the liver and circulation of chronic HBV patients are correlated with the degree of liver damage and virus control.
19. Lauvau G., Kakimi K., Niedermann G., Ostankovitch M., Yotnda P., Firat H., Chisari F., van Endert P. Human transporter associated with antigen processing (TAPs) select epitope precursor peptides for processing in the endoplasmic reticulum and presentation to T cells. J Exp Med. 190:1999;1227-1239.
20. Bertoletti A., D'Elios M.M., Boni C., De Carli M., Zignego A.L., Durazzo M., Missale G., Penna A., Fiaccadori F., Del Prete G., Ferrari C. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology. 112:1997;193-199.
21. Minutello M.A., Pileri P., Unutmaz D., Censini S., Kuo G., Houghton M., Brunetto M.R., Bonino F., Abrignani S. Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med. 178:1993;17-25.
22. Ando K., Moriyama T., Guidotti L.G., Wirth S., Schreiber R., Schlicht H., Huang S., Chisari F.V. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med. 178:1993;1541-1554.
23. Tiegs G., Hentschel J., Wendel A. A T-cell dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest. 90:1992;196-203.
24. Kusters S., Gantner F., Kunstle G., Tiegs G. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology. 111:1996;462-471.
25. Moskophidis D., Kioussis D. Contribution of virus-specific CD8+ cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. J Exp Med. 188:1998;223-232.
26. Young H.A., Hardy K.J. Role of interferon-gamma in immune cell regulation. J Leukoc Biol. 58:1995;373-381.
27. Morita M., Watanabe Y., Akaike T. Protective effect of hepatocyte growth factor on interferon-gamma-induced cytotoxicity in mouse hepatocytes. Hepatology. 21:1995;1585-1593.
28. Taub D.D., Conlon K., Lloyd A.R., Oppenheim J.J., Kelvin D.J. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1α and MIP-1β Science. 260:1993;355-357.
29. Cook D., Beck M., Coffman T., Kirby S., Sheridan J., Pragnell I., Smithies O. Requirement of MIP-1α for an inflammatory response to viral infection. Science. 269:1995;1583-1586.
30. Shields P.L., Morland C.M., Salmon M., Qin S., Hubscher S.G., Adams D.H. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C infected liver. J Immunol. 163:1999;6236-6243. Links the expression of different chemokines and chemokine receptors to preferential T cell recruitment to specific anatomical sites within an HCV-infected liver.
31. Salazar-Mather T.P., Orange J.S., Biron C.A. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1α (MIP-1α)-dependent pathways. J Exp Med. 187:1998;1-14.
32. Kaneko Y.B., Harada M., Kawano T., Yamashita M., Shibata Y., Gejco F., Nakayama T., Taniguchi M. Augmentation of Vα14 NKT cell-mediated cytotoxicity by interleukin-4 in an autocrine mechanism resulting in the development of Concanavalin A-induced hepatitis. J Exp Med. 191:2000;105-114. Demonstrates the importance of NKT cells and of perforin/Fas-ligand molecules in the development of liver inflammation.
33. Toyonaga T., Hino O., Sugai S., Wakasugi S., Abe K., Shichiri M., Yamamura K. Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. Proc Natl Acad Sci USA. 91:1994;614-618.
34. Napoli J., Bishop G.A., McGuinness P.H., Painter D.M., McCaughan G.W. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology. 24:1996;759-765.
35. Marinos G., Rossol S., Carucci P., Wong P.Y., Donaldson P., Hussain M.J., Vergani D., Portmann B.C., Williams R., Naoumov N.V. Immunopathogenesis of hepatitis B virus recurrence after liver transplantation. Transplantation. 69:2000;559-568.
36. Afford S.C., Randhawa S., Eliopoulos A.G., Hubscher S.G., Young L.S., Adams D.H. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface Fas ligand expression and amplifies Fas-mediated hepatocyte death during allograft rejection. J Exp Med. 189:1999;441-446. Engagement of the CD40 molecule in hepatocytes amplifies Fas-dependent hepatocyte death - a proposed mechanism of liver damage that may be active in a broad range of inflammatory liver diseases.
37. Chazouilleres O., Mamish D., Kim M., Carey K., Ferrel L., Roberts J., Acsher N.L., Wright T.L. "Occult" hepatitis B virus as a source of infection in liver transplant recipients. Lancet. 343:1994;142-146.
38. Cacciola I., Pollicino T., Squadrito G., Cerenzia G., Orlando M.E., Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 341:1999;22-26.
39. Michalak T.I., Pasquinelli S., Guilhot S., Chisari F.V. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest. 93:1994;230-239.
40. Penna A., Artini M., Cavalli A., Levrero M., Bertoletti A., Pilli M., Chisari F.V., Rehermann B., Del Prete G., Fiaccadori F., Ferrari C. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest. 98:1996;1185-1194.
41. Rehermann B., Ferrari C., Pasquinelli C., Chisari F.V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 2:1996;1104-1108.
42. Marusawa H., Uemoto S., Hijikata M., Ueda Y., Tanaka K., Shimothono K., Chiba T. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology. 31:2000;488-495.
43. Cacciola I., Pollicino T., Squadrito G., Cerenzia G., Villari D., De Franchis R., Sanantonio T., Brancatelli S., Colucci G., Raimondo G. Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatology. 31:2000;507-512.
44. Mason A.L., Xu L., Guo L., Kuhns M., Perrillo R.P. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology. 27:1998;1736-1742.
45. Parker C.E., Nightingale S., Taylor G.P., Weber J., Bangham C.R. Circulating anti-Tax cytotoxic T lymphocytes from human T-cell leukaemia virus type I-infected people, with and without tropical spastic paraparesis, recognize multiple epitopes simultaneously. J Virol. 68:1994;2860-2868.
46. Tan L.C., Gudgeon N., Annels N.E., Hansasuta P., O'Callaghan C.A., Rowland-Jones S., McMichael A.J., Rickinson A.B., Callan M.F. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol. 162:1999;1827-1835.
47. Liu T., Khanna K.M., Chen X.P., Fink D.J., Hendricks R.L. CD8+ T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med. 191:2000;1459-1466.
48. Nowak M.A., Bangham C.R. Population dynamics of immune responses to persistent viruses. Science. 272:1996;74-79.
49. Bertoletti A., Sette A., Chisari F.V., Penna A., Levrero M., De Carli M., Fiaccadori F., Ferrari C. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature. 369:1994;407-410.
50. Tsai S.L., Chen Y.M., Chen M.H., Huang C.Y., Sheen I.S., Yeh C.T., Huang J.H., Kuo G.C., Liaw Y.F. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology. 115:1998;954-966.
51. Cote P.J., Korba B.E., Miller R.H., Jacob J.R., Baldwin B.H., Hornbuckle W.E., Purcell R.H., Tennant B.C., Gerin J.L. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. Hepatology. 31:2000;190-200.
52. Ehl S., Klenerman P., Aichele P., Hengartner H., Zinkernagel R.M. A functional and kinetic comparison of antiviral effector and memory cytotoxic T lymphocyte populations in vivo and in vitro. Eur J Immunol. 27:1997;3404-3413.
53. Cerwenka A., Morgan T.M., Harmsen A.G., Dutton R.W. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. J Exp Med. 189:1999;423-434. The migration potential of CTLs is shown to influence the outcome of virus infection.
54. Rehermann B., Fowler P., Sidney J., Person J., Redeker A., Brown M., Moss B., Sette A., Chisari F.V. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med. 181:1995;1047-1058.
55. Ferrari C., Penna A., Bertoletti A., Valli A., Degli Antoni A., Giuberti T., Cavalli A., Petit M.A., Fiaccadori F. Cellular immune response to hepatitis B virus encoded antigens in acute and chronic hepatitis B virus infection. J Immunol. 145:1990;3442-3449.
56. Jung M., Spengler U., Schraut W., Hoffman R., Zachoval R., Eisemburg J., Eichenlaub D., Riethmuller G., Paumgartner G., Ziegler-Heitbrock H.W.L., Pape G.R. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol. 13:1991;310-317.
57. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., Rumi M., Houghton M., Fiaccadori F., Ferrari C. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest. 98:1996;706-714.
58. Diepolder H.M., Zachoval R., Hoffmann R.M., Wierenga E., Santantonio T., Jung M.C., Eichenlaub D., Pape G.R. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 346:1995;1006-1007.
59. Gerlach J., Diepolder H.M., Jung M.C., Gruener N., Schraut W., Zachoval R., Hoffmann R.M., Schirren C., Santantonio T., Pape G. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology. 117:1999;933-941.
60. Cramp M.E., Carucci P., Rossol S., Chokshi S., Maertens G., Williams R., Naoumov N.V. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients with hepatitis C viraemia. Gut. 44:1999;424-429.
61. Nuti S., Rosa D., Valiante N., Saletti G., Caratazzolo M., Dellabona P., Barnaba V., Abrignani S. Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Vα 24+ T cells and rapid elimination of effector cell by apoptosis. Eur J Immunol. 28:1998;3448-3455.
62. Biron C. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol. 9:1997;24-34.
63. Spriggs M.K. One step ahead of the game: viral immunomodulatory molecules. Annu Rev Immunol. 14:1996;101-130.
64. Lalani A.S., Barrett J.W., McFadden G. Modulating chemokines: more lessons from viruses. Immunol Today. 21:2000;100-106.
65. Large M.K., Kittlesen D.J., Hahn Y.S. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol. 162:1999;931-938.
66. Heim M.H., Moradpour D., Blum H.E. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol. 73:1999;8469-8475.
67. Taylor D.R., Shi S.T., Romano P.R., Barber G., Lai M. Inhibition of interferon-inducible protein kinase PKR by HCV E2 protein. Science. 285:1999;107-110.
68. Livingston B.D., Alexander J., Crimi C., Oseroff C., Celis E., Daly K., Guidotti L.G., Chisari F.V., Fikes J., Chesnut R.W., Sette A. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol. 162:1999;3088-3095.
69. Boni C., Bertoletti A., Penna A., Cavalli A., Pilli M., Urbani S., Scognamiglio P., Boheme R., Panebianco R., Fiaccadori F., Ferrari C. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest. 102:1998;968-975.
70. Nakamoto Y., Guidotti L.G., Kuhlen C., Fowler P., Chisari F.V. Immune pathogenesis of hepatocellular carcinoma. J Exp Med. 188:1998;341-350.